Sanna-Kaisa Herukka

List of Publications by Year
in descending order

81 papers	3,930 citations	218381 26 h-index	128067 60 g-index
82 all docs	82 docs citations	82 times ranked	6279 citing authors

#	Article	IF	Citations
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
2	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	3.7	284
3	The cerebrospinal fluid "Alzheimer profile". Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
4	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
5	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.4	113
6	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.4	108
7	Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	3.7	107
8	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large‐scale international multicenter study. Alzheimer's and Dementia, 2015, 11, 1306-1315.	0.4	104
9	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
10	Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus. PLoS ONE, 2014, 9, e91974.	1.1	91
11	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	6.0	85
12	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
13	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.1	84
14	Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. Journal of Neurology, 2020, 267, 162-167.	1.8	70
15	Increased Levels of the Bullous Pemphigoid BP180 Autoantibody Are Associated with More Severe Dementia in Alzheimer's Disease. Journal of Investigative Dermatology, 2017, 137, 71-76.	0.3	62
16	CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1117-1123.	0.9	61
17	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
18	Effects of Alzheimer's Disease-Associated Risk Loci on Cerebrospinal Fluid Biomarkers and Disease Progression: A Polygenic Risk Score Approach. Journal of Alzheimer's Disease, 2014, 43, 565-573.	1.2	49

#	Article	IF	Citations
19	Prognostic Polypeptide Blood Plasma Biomarkers of Alzheimer's Disease Progression. Journal of Alzheimer's Disease, 2014, 40, 659-666.	1.2	44
20	Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 142-149.	0.6	41
21	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	3.0	40
22	Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 2242-2249.	0.7	40
23	Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2015, 46, 261-269.	1.2	39
24	Decreased plasma β‐amyloid in the Alzheimer's disease *APP*A673T variant carriers. Annals of Neurology, 2017, 82, 128-132.	2.8	39
25	Chasing the Effects of Pre-Analytical Confounders – A Multicenter Study on CSF-AD Biomarkers. Frontiers in Neurology, 2015, 6, 153.	1.1	38
26	Predicting Development of Alzheimer's Disease in Patients with Shunted Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2019, 71, 1233-1243.	1.2	28
27	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27
28	GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1305-1312.	0.9	25
29	Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data. Scientific Reports, 2016, 6, 26145.	1.6	24
30	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1387-1395.	1.2	24
31	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. Alzheimer's Research and Therapy, 2019, 11, 25.	3.0	23
32	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. Current Alzheimer Research, 2019, 16, 91-101.	0.7	23
33	Neurofilament Light Regulates Axon Caliber, Synaptic Activity, and Organelle Trafficking in Cultured Human Motor Neurons. Frontiers in Cell and Developmental Biology, 2021, 9, 820105.	1.8	23
34	Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations. Alzheimer's Research and Therapy, 2017, 9, 87.	3.0	22
35	Multimodal analysis to predict shunt surgery outcome of 284 patients with suspected idiopathic normal pressure hydrocephalus. Acta Neurochirurgica, 2016, 158, 2311-2319.	0.9	21
36	Circulating neurofilament is linked with morbid obesity, renal function, and brain density. Scientific Reports, 2022, 12, 7841.	1.6	21

#	Article	IF	Citations
37	BP180 Autoantibodies Target Different Epitopes in Multiple Sclerosis or Alzheimer's Disease than in Bullous Pemphigoid. Journal of Investigative Dermatology, 2019, 139, 293-299.	0.3	20
38	Alterations in mitochondria-endoplasmic reticulum connectivity in human brain biopsies from idiopathic normal pressure hydrocephalus patients. Acta Neuropathologica Communications, 2018, 6, 102.	2.4	19
39	Prevalence of immunological diseases in a Finnish frontotemporal lobar degeneration cohort with the C9orf72 repeat expansion carriers and non-carriers. Journal of Neuroimmunology, 2018, 321, 29-35.	1.1	19
40	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18
41	Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients. Fluids and Barriers of the CNS, 2022, 19, 11.	2.4	18
42	Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events. In Vivo, 2020, 34, 2577-2586.	0.6	17
43	Serum neurofilament light chain in FTLD: association with C9orf72, clinical phenotype, and prognosis. Annals of Clinical and Translational Neurology, 2020, 7, 903-910.	1.7	17
44	S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies. Journal of Alzheimer's Disease, 2018, 64, 171-179.	1.2	14
45	Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103280.	0.9	14
46	The CERAD Neuropsychological Battery in Patients with Frontotemporal Lobar Degeneration. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 147-154.	0.6	13
47	Low Serum High-Density Lipoprotein Cholesterol Levels Associate with the C9orf72 Repeat Expansion in Frontotemporal Lobar Degeneration Patients. Journal of Alzheimer's Disease, 2019, 72, 127-137.	1.2	13
48	[11C]PIB PET Is Associated with the Brain Biopsy Amyloid-β Load in Subjects Examined for Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2019, 67, 1343-1351.	1.2	13
49	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2020, 76, 1061-1070.	1.2	13
50	Metabolic Profiles Help Discriminate Mild Cognitive Impairment from Dementia Stage in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 277-286.	1.2	13
51	Comparison Between Clinical Diagnosis and CSF Biomarkers of Alzheimer Disease in Elderly Patients with Late Onset Psychosis: Helsinki Old Age Psychosis Study (HOPS). American Journal of Geriatric Psychiatry, 2014, 22, 908-916.	0.6	12
52	Using the Disease State Fingerprint Tool for Differential Diagnosis of Frontotemporal Dementia and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 313-329.	0.6	12
53	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12
54	Elevated CSF LRG and Decreased Alzheimer's Disease Biomarkers in Idiopathic Normal Pressure Hydrocephalus. Journal of Clinical Medicine, 2021, 10, 1105.	1.0	12

#	Article	IF	Citations
55	Low Cerebrospinal Fluid Amyloid-Beta Concentration Is Associated with Poorer Delayed Memory Recall in Women. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 303-312.	0.6	10
56	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
57	Cerebrospinal Fluid and MRI Biomarkers in Neurodegenerative Diseases: A Retrospective Memory Clinic-Based Study. Journal of Alzheimer's Disease, 2020, 75, 751-765.	1.2	10
58	Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2021, 80, 1629-1642.	1.2	10
59	Subtle Cognitive Impairment and Alzheimer's Disease-Type Pathological Changes in Cerebrospinal Fluid are Common Among Neurologically Healthy Subjects. Journal of Alzheimer's Disease, 2018, 62, 165-174.	1.2	9
60	Low Prevalence of Cancer in Patients with Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2018, 62, 789-794.	1.2	9
61	Threshold of heteroplasmic truncating MT-ATP6 mutation in reprogramming, Notch hyperactivation and motor neuron metabolism. Human Molecular Genetics, 2022, 31, 958-974.	1.4	9
62	Peripheral inflammatory markers and clinical correlations in patients with frontotemporal lobar degeneration with and without the C9orf72 repeat expansion. Journal of Neurology, 2020, 267, 76-86.	1.8	8
63	Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients. Brain and Behavior, 2020, 10, e01772.	1.0	7
64	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. PLoS ONE, 2020, 15, e0226784.	1.1	7
65	Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by CHMP2B Mutation. Dementia and Geriatric Cognitive Disorders, 2020, 49, 533-538.	0.7	7
66	The Association Between Frontotemporal Lobar Degeneration and Bullous Pemphigoid. Journal of Alzheimer's Disease, 2018, 66, 743-750.	1.2	6
67	A novel CT-based automated analysis method provides comparable results with MRI in measuring brain atrophy and white matter lesions. Neuroradiology, 2021, 63, 2035-2046.	1.1	6
68	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2021, 79, 163-175.	1.2	5
69	O1-01-01: Cerebrospinal fluid biomarkers for Alzheimer's disease are associated with neuropathology in cortical brain biopsy. , 2012, 8, P83-P84.		0
70	P4-063: APOE GENOTYPE AND CSF Aβ42 IN COGNITIVELY HEALTHY INDIVIDUALS. , 2014, 10, P806-P806.		0
71	P1-128: C9ORF72 EXPANSION DOES NOT HAVE EFFECTS ON CSF TDP-43 LEVELS IN FTLD PATIENTS. , 2014, 10, P347-P347.		0
72	P1-328: CONSISTENCY OF MUISTIKKO WEB-BASED COGNITIVE TEST WHILE PERFORMED AT CLINIC AND AT HOME. Alzheimer's and Dementia, 2018, 14, P418.	0.4	0

#	Article	IF	Citations
73	P1â€251: CSFâ€NEUROGRANIN, BUT NOT BACE1, IS AN ALZHEIMER'S DISEASE SPECIFIC BIOMARKER. Alzheimer's and Dementia, 2018, 14, P376.	0.4	0
74	P2â€421: THE CORRELATION BETWEEN CSF BIOMARKERS AND VOLUMETRIC ATROPHY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P870.	0.4	0
75	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. Alzheimer's and Dementia, 2020, 16, e040152.	0.4	0
76	Differential diagnosis of dementia combining webâ€based cognitive testing and MRI. Alzheimer's and Dementia, 2020, 16, e042626.	0.4	0
77	Computerized decision support to select memory clinic patients for amyloid PET: Which patient to test?. Alzheimer's and Dementia, 2020, 16, e042687.	0.4	0
78	Title is missing!. , 2020, 15, e0226784.		0
79	Title is missing!. , 2020, 15, e0226784.		0
80	Title is missing!. , 2020, 15, e0226784.		0
81	Title is missing!. , 2020, 15, e0226784.		0